2bgn: Difference between revisions

Revision as of 17:37, 21 February 2008

HIV-1 TAT PROTEIN DERIVED N-TERMINAL NONAPEPTIDE TRP2-TAT (1-9) BOUND TO THE ACTIVE SITE OF DIPEPTIDYL PEPTIDASE IV (CD26)

OverviewOverview

CD26 or dipeptidyl-peptidase IV (DPPIV) is engaged in immune functions by co-stimulatory effects on activation and proliferation of T lymphocytes, binding to adenosine deaminase, and regulation of various chemokines and cytokines. DPPIV peptidase activity is inhibited by both Tat protein from human immunodeficiency virus (HIV)-1 and its N-terminal nonapeptide Tat-(1-9) with amino acid sequence MDPVDPNIE, suggesting that DPPIV mediates immunosuppressive effects of Tat protein. The 2.0- and 3.15-A resolution crystal structures of the binary complex between human DPPIV and nonapeptide Tat-(1-9) and the ternary complex between the variant MWPVDPNIE, called Trp(2)-Tat-(1-9), and DPPIV bound to adenosine deaminase show that Tat-(1-9) and Trp(2)-Tat-(1-9) are located in the active site of DPPIV. The interaction pattern of DPPIV with Trp(2)-Tat-(1-9) is tighter than that with Tat-(1-9), in agreement with inhibition constants (K(i)) of 2 x 10(-6) and 250 x 10(-6) m, respectively. Both peptides cannot be cleaved by DPPIV because the binding pockets of the N-terminal 2 residues are interchanged compared with natural substrates: the N-terminal methionine occupies the hydrophobic S1 pocket of DPPIV that normally accounts for substrate specificity by binding the penultimate residue. Because the N-terminal sequence of the thromboxane A2 receptor resembles the Trp(2)-Tat-(1-9) peptide, a possible interaction with DPPIV is postulated.

About this StructureAbout this Structure

2BGN is a Protein complex structure of sequences from Bos taurus and Homo sapiens with and as ligands. Active as Dipeptidyl-peptidase IV, with EC number 3.4.14.5 Known structural/functional Site: . Full crystallographic information is available from OCA.

ReferenceReference

Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26)., Weihofen WA, Liu J, Reutter W, Saenger W, Fan H, J Biol Chem. 2005 Apr 15;280(15):14911-7. Epub 2005 Jan 28. PMID:15695814

Page seeded by OCA on Thu Feb 21 16:37:36 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 4: / Line 4: @@
 ==Overview==
-CD26 or dipeptidyl-peptidase IV (DPPIV) is engaged in immune functions by, co-stimulatory effects on activation and proliferation of T lymphocytes, binding to adenosine deaminase, and regulation of various chemokines and, cytokines. DPPIV peptidase activity is inhibited by both Tat protein from, human immunodeficiency virus (HIV)-1 and its N-terminal nonapeptide, Tat-(1-9) with amino acid sequence MDPVDPNIE, suggesting that DPPIV, mediates immunosuppressive effects of Tat protein. The 2.0- and 3.15-A, resolution crystal structures of the binary complex between human DPPIV, and nonapeptide Tat-(1-9) and the ternary complex between the variant, MWPVDPNIE, called Trp(2)-Tat-(1-9), and DPPIV bound to adenosine deaminase, show that Tat-(1-9) and Trp(2)-Tat-(1-9) are located in the active site of, DPPIV. The interaction pattern of DPPIV with Trp(2)-Tat-(1-9) is tighter, than that with Tat-(1-9), in agreement with inhibition constants (K(i)) of, 2 x 10(-6) and 250 x 10(-6) m, respectively. Both peptides cannot be, cleaved by DPPIV because the binding pockets of the N-terminal 2 residues, are interchanged compared with natural substrates: the N-terminal, methionine occupies the hydrophobic S1 pocket of DPPIV that normally, accounts for substrate specificity by binding the penultimate residue., Because the N-terminal sequence of the thromboxane A2 receptor resembles, the Trp(2)-Tat-(1-9) peptide, a possible interaction with DPPIV is, postulated.
+CD26 or dipeptidyl-peptidase IV (DPPIV) is engaged in immune functions by co-stimulatory effects on activation and proliferation of T lymphocytes, binding to adenosine deaminase, and regulation of various chemokines and cytokines. DPPIV peptidase activity is inhibited by both Tat protein from human immunodeficiency virus (HIV)-1 and its N-terminal nonapeptide Tat-(1-9) with amino acid sequence MDPVDPNIE, suggesting that DPPIV mediates immunosuppressive effects of Tat protein. The 2.0- and 3.15-A resolution crystal structures of the binary complex between human DPPIV and nonapeptide Tat-(1-9) and the ternary complex between the variant MWPVDPNIE, called Trp(2)-Tat-(1-9), and DPPIV bound to adenosine deaminase show that Tat-(1-9) and Trp(2)-Tat-(1-9) are located in the active site of DPPIV. The interaction pattern of DPPIV with Trp(2)-Tat-(1-9) is tighter than that with Tat-(1-9), in agreement with inhibition constants (K(i)) of 2 x 10(-6) and 250 x 10(-6) m, respectively. Both peptides cannot be cleaved by DPPIV because the binding pockets of the N-terminal 2 residues are interchanged compared with natural substrates: the N-terminal methionine occupies the hydrophobic S1 pocket of DPPIV that normally accounts for substrate specificity by binding the penultimate residue. Because the N-terminal sequence of the thromboxane A2 receptor resembles the Trp(2)-Tat-(1-9) peptide, a possible interaction with DPPIV is postulated.
 ==About this Structure==
@@ Line 19: / Line 19: @@
 [[Category: Reutter, W.]]
 [[Category: Saenger, W.]]
-[[Category: Weihofen, W.A.]]
+[[Category: Weihofen, W A.]]
 [[Category: NAG]]
 [[Category: ZN]]
@@ Line 34: / Line 34: @@
 [[Category: serine protease]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb  3 10:23:49 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:37:36 2008''